ONX-0914
Code | Size | Price |
---|
TAR-T6029-1mg | 1mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6029-5mg | 5mg | £168.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6029-1mL | 1 mL * 10 mM (in DMSO) | £197.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6029-10mg | 10mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6029-25mg | 25mg | £337.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6029-50mg | 50mg | £470.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
ONX-0914 is an effective and specific immunoproteasome inhibitor, which has minimal cross-reactivity for the constitutive proteasome.
CAS:
960374-59-8
Formula:
C31H40N4O7
Molecular Weight:
580.682
Pathway:
Microbiology/Virology; Ubiquitination; Proteases/Proteasome
Purity:
0.9835
SMILES:
COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1
Target:
Proteasome; HIV Protease; Antibacterial
References
Li Y, Nan G, Hou X, et al.Non-peptidic immunoproteasome ?5i-Selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.European Journal of Medicinal Chemistry.2023: 115856.
Muchamuel T, et al. Nat Med, 2009, 15(7), 781-787.
Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-?B pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326.
Guo T, Liu C, Yang C, et al. Immunoproteasome subunit PSMB8 regulates microglia-mediated neuroinflammation upon manganese exposure by PERK signaling. Food and Chemical Toxicology. 2022: 112951.